Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: Part II

Urologic Oncology: Seminars and Original Investigations

Volumn 22, Issue 6, 2004, Pages 472-477

  Moyad, Mark A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Cancer; Cardiovascular disease; Cholesterol; Heart disease; Prostate cancer; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ATORVASTATIN; CYCLOOXYGENASE 2 INHIBITOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; PROSTATE SPECIFIC ANTIGEN; REFECOXIB; SELENIUM; SIMVASTATIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARDIOVASCULAR AGENT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DYSLIPIDEMIA; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; UPREGULATION; ADULT; FEMALE; MALE; METHODOLOGY; MORTALITY; NEOPLASM; REVIEW;

ADULT; ANTICARCINOGENIC AGENTS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHEMOPREVENTION; CLINICAL TRIALS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASMS;

EID: 18844430757     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2004.10.002     Document Type: Conference Paper

References (35)

1. C.J. Newschaffer, K. Otani, M.K. McDonald Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort J Natl Cancer Inst 92 2000 613 621
2. M.A. Moyad Selenium and vitamin E supplements for prostate cancer evidence or embellishment? Urology 59 suppl. 4A 2002 9 19
3. K. Senior Atherosclerosis gene increases susceptibility to prostate cancer Lancet 360 2002 928
4. M. Sonnleithner, K. Jeschke, L. Bayer Dyslipoproteinemia as a risk factor in prostate cancer J Urol 169 2003 76 [abstract 294]
5. M.R. Graaf, A.B. Beiderbeck, A.C.G. Egberts The risk of cancer in users of statins J Clin Oncol 22 2004 2388 2394
6. J.A. Cauley, J.M. Zmuda, L.Y. Lui Lipid-lowering drug use and breast cancer in older women a prospective study J Womens Health 12 2003 749 756
7. J. Shannon, M. Garzotto, A.J. Palma Statin use and prostate cancer risk Proceedings of the American Society of Clinical Oncology 23 2004 404 [abstract 4596].
8. J.N. Poynter, G. Rennert, J.D. Bonner HMG CoA reductase inhibitors and the risk of colorectal cancer Proceedings of the American Society of Clinical Oncology 23 2004 1 [abstract 1]
9. M.O. Katz, M.J. Zelefsky, C. Marion Statin use is associated with improved biochemical outcome after high-dose radiotherapy for clinically localized prostate cancer Proceedings of the 45th Annual ASTRO Meeting 2003 S271 [abstract 1016].
10. M.R. Freeman, K.R. Solomon Cholesterol and prostate cancer J Cellular Biochem 91 2004 54 69
11. R.M. White On the occurrence of crystals in tumours J Pathol Bacteriol 13 1909 3 10
12. C.P. Schaffner Prostatic cholesterol metabolism Regulation and alteration R. Alan The Prostatic Cell Structure and Function 1981 Liss, Inc New York, NY 279 324
13. H.G. Farina, D.R. Bublik, D.F. Alonso Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells Clin Exp Metastasis 19 2002 551 559
14. C. Ukomadu, A. Dutta Inhibition of cdk2 activating phosphorylation by mevastatin J Biol Chem 278 2003 4840 4846
15. W.W. Wong, M.M. Tan, Z. Xia Cervistatin triggers tumor-specific apoptosis with higher efficacy than lovastatin Clin Cancer Res 7 2001 2067 2075
16. C.P. Schaffner, H.W. Gordon The hypocholesterolemic activity of orally administered polyene macrolides Proc Natl Acad Sci USA 61 1968 36 41
17. M. Hughes-Fulford, Y. Chen, R.R. Tjandrawinata Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells Carcinogenesis 22 2001 701 707
18. G. Swyer The cholesterol content of normal and enlarged prostates Cancer Res 2 1942 372 375
19. S. Kawata, E. Yamasaki, T. Nagase Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial Brit J Cancer 84 2001 886 891
20. S. Moorjani, A. Dupont, F. Labrie Increase in plasma high-density lipoprotein concentration following complete androgen blockade in men with prostatic carcinoma Metabolism 36 1987 244 250
21. F.B. Kraemer, A. Pont Inhibition of cholesterol synthesis by ketoconazole Am J Med 80 1986 616 622
22. G.W. Stone, S.G. Ellis, D.A. Cox Taxus-IV Investigators A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231
23. B. Wolozin, W. Kellman, P. Ruosseau Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors Arch Neurol 57 2000 1439 1443
24. J.C. Coons Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management Ann Pharmacother 36 2002 326 330
25. M.A. Moyad Lifestyle changes to prevent BPH heart healthy=prostate healthy Urol Nurs 23 2003 439 441
26. H. Solomon, J.W. Man, Wierzbicki Relation of erectile dysfunction to angiographic coronary artery disease Am J Cardiol 91 2003 230 231
27. A.I. El-Sakka, A.M. Morsy, B.I. Fagih Coronary artery risk factors in patients with erectile dysfunction J Urol 172 2004 251 254
28. E.A. Saltzman, A.T. Guay, J. Jacobson Improvement in erectile function in men with organic erectile dysfunction by correction of elevated cholesterol levels a clinical observation J Urol 172 2004 255 258
29. M.A. Moyad The use of complementary/preventive medicine to prevent prostate cancer recurrence/progression following definitive therapy. Part II-rapid review of dietary supplements Curr Opin Urol 13 2003 147 151
30. M.B. Terry, M.D. Gammon, F.F. Zhang Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk JAMA 291 2004 2433 2440
31. M.A. Moyad An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis part I Semin Urol Oncol 19 2001 294 305
32. M.A. Moyad An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis part II Semin Urol Oncol 19 2001 306 316
33. R.O. Roberts, D.J. Jacobson, C.J. Girman A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer Mayo Clin Proc 77 2002 219 225
34. W.S. Harris Fish oil supplementation evidence for health benefits Cleve Clin J Med 71 2004 208 221
35. P.F. Coogan, L. Rosenberg, J.R. Palmer Statin use and the risk of breast and prostate cancer Epidemiology 13 2002 262 267